POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort

Kaye, E., Osborne, T., Thornton, L. et al. (4 more authors) (2025) POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. Vol. 84 (Supplement 1). BMJ Publishing Group, p. 730. ISSN: 0003-4967. EISSN: 1468-2060.

Metadata

Item Type:	Conference abstract
Authors/Creators:	Kaye, E. Osborne, T. Thornton, L. Di Donato, S. Kakkar, V. Del Galdo, F. https://orcid.org/0000-0002-8528-2283 Bissell, L.A.
Dates:	Accepted: 26 March 2025 Published: June 2025
Institution:	The University of Leeds
Academic Units:	The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Date Deposited:	18 Jul 2025 13:34
Last Modified:	05 Mar 2026 12:13
Status:	Published
Publisher:	BMJ Publishing Group
Identification Number:	10.1016/j.ard.2025.05.898
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:229308

CORE (COnnecting REpositories)

POS0516 Applicability of the phase 3 Trial DAISY (Detecting effectiveness of Anifrolumab In SYstemic Sclerosis) inclusion criteria to the general SSc population – a study from the EUSTAR cohort

Metadata

Download not available

Export

Statistics